Modulation of the Pancreatic Hormone, Glucagon by the Gut Peptide, GLP-1: Controversies, Challenges and Future Directions

Conference paper
First Online:

Abstract

Type 2 diabetes (T2D) is a chronic disease characterised by a combination of insufficient insulin release and an excess of glucagon secretion. The gut hormone glucagon-like peptide-1 (GLP-1) is a successful therapy for the treatment of diabetes as it can both potentiate glucose-induced insulin secretion as well as inhibit glucagon secretion from the pancreatic alpha cells. Another major gut hormone called peptide tyrosine tyrosine (PYY) has recently been reported to restore impaired insulin and glucagon secretion in islets from severely diabetic rats and humans. Whilst the mechanism by which both PYY and GLP-1 normalise insulin secretion is well characterised, to date the regulation of glucagon release by the two gut hormones remains unclear. Given that the GLP-1 receptor is expressed at extremely low levels on alpha-cells, it has been argued that the effects of GLP-1 may be mediated by paracrine (indirect) mechanisms. In contrast, there is also evidence that GLP-1 directly regulates glucagon secretion in isolated alpha-cells, excluding the possibility of islet cross-talk. Likewise, no receptors for PYY have been demonstrated in the alpha-cells that can explain the robust effects of the hormone on glucagon release. Elucidation of the mechanism of GLP-1 (and PYY) action on alpha cells necessitates further work. Specifically it will be important to determine if GLP-1 can mediate its effects via another receptor on alpha-cells.

This is a preview of subscription content, log in to check access.

References

  1. 1.
    Holst JJ, Christensen M, Lund A, de Heer J, Svendsen B, Kielgast U et al (2011) Regulation of glucagon secretion by incretins. Diabetes Obes Metab 13(Suppl 1):89–94CrossRefGoogle Scholar
  2. 2.
    Xue X, Ren Z, Zhang A, Yang Q, Zhang W, Liu F (2016) Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials. Int J Clin Pract 70:649–656CrossRefGoogle Scholar
  3. 3.
    Samson SL, Garber AJ (2016) A plethora of GLP-1 agonists: decisions about what to use and when. Curr Diab Rep 16:120CrossRefGoogle Scholar
  4. 4.
    Ramracheya RD, McCulloch LJ, Clark A, Wiggins D, Johannessen H, Olsen MK et al (2016) PYY-dependent restoration of impaired insulin and glucagon secretion in Type 2 diabetes following Roux-En-Y gastric bypass surgery. Cell Rep 15:944–950CrossRefGoogle Scholar
  5. 5.
    Tornehave D, Kristensen P, Rømer J, Knudsen LB, Heller RS (2008) Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 56:841–851CrossRefGoogle Scholar
  6. 6.
    De Marinis YZ, Salehi A, Ward CE, Zhang Q, Abdulkader F, Bengtsson M et al (2010) GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis. Cell Metab 11:543–553CrossRefGoogle Scholar
  7. 7.
    Pyke C, Heller RS, Kirk RK, Orskov C, Reedtz-Runge S, Kaastrup P et al (2014) GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155:1280–1290CrossRefGoogle Scholar
  8. 8.
    Rorsman P, Ramracheya R, Rorsman NJ, Zhang Q (2014) ATP-regulated potassium channels and voltage-gated calcium channels in pancreatic alpha and beta cells: similar functions but reciprocal effects on secretion. Diabetologia 57:1749–1761CrossRefGoogle Scholar
  9. 9.
    Drucker DJ (2013) Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 62:3316–3323CrossRefGoogle Scholar
  10. 10.
    Robinson E, Tate M, Lockhart S et al (2016) Metabolically-inactive glucagon-like peptide-1(9–36)amide confers selective protective actions against post-myocardial infarction remodelling. Cardiovasc Diabetol 15:65CrossRefGoogle Scholar
  11. 11.
    Rorsman P, Braun M (2013) Regulation of insulin secretion in human pancreatic islets. Annu Rev Physiol 75:155–179CrossRefGoogle Scholar
  12. 12.
    Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of MedicineUniversity of OxfordOxfordUK

Personalised recommendations